Harmony Biosciences Holdings, Inc. (HRMY)
NASDAQ: HRMY · Real-Time Price · USD
38.41
-0.34 (-0.88%)
Aug 7, 2026, 4:00 PM EDT - Market closed
HRMY Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 549.77 | 752.5 | 453 | 311.66 | 243.78 | 234.31 |
Short-Term Investments | 118.02 | 22.84 | 14.19 | 41.8 | 79.33 | - |
Cash & Short-Term Investments | 667.79 | 775.34 | 467.19 | 353.46 | 323.12 | 234.31 |
Cash Growth | 18.14% | 65.96% | 32.17% | 9.39% | 37.90% | 2.48% |
Accounts Receivable | 111 | 96.79 | 83.03 | 74.14 | 54.74 | 34.84 |
Inventory | 6.36 | 5.36 | 7.2 | 5.36 | 4.3 | 4.43 |
Other Current Assets | 29.19 | 29.53 | 21.84 | 18.11 | 18.13 | 10.86 |
Total Current Assets | 814.33 | 907.01 | 579.25 | 451.07 | 400.29 | 284.44 |
Net Property, Plant & Equipment | - | - | - | 0.37 | 0.57 | 0.82 |
Other Intangible Assets | 77.5 | 89.42 | 113.26 | 137.11 | 160.95 | 143.92 |
Long-Term Investments | 294.67 | 107.13 | 108.87 | 72.17 | 22.57 | - |
Other Long-Term Assets | 186.59 | 168.07 | 197.81 | 150.73 | 89.49 | 4.27 |
Total Assets | 1,373 | 1,272 | 999.2 | 811.45 | 673.87 | 433.44 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 21.68 | 17.69 | 13.74 | 17.73 | 3.79 | 1 |
Accrued Expenses | 181.22 | 209.48 | 139.42 | 123.24 | 71.47 | 49.41 |
Current Portion of Long-Term Debt | 20 | 20 | 16.25 | 15 | 2 | 2 |
Other Current Liabilities | 11.17 | 4.96 | 5.67 | 7.81 | 1.62 | 1.36 |
Total Current Liabilities | 234.07 | 252.13 | 175.08 | 163.78 | 78.88 | 53.78 |
Long-Term Debt | 133.96 | 143.66 | 163.02 | 178.57 | 189.65 | 189.98 |
Other Long-Term Liabilities | 5.81 | 5.62 | 1.95 | 2.11 | 2.5 | 3.18 |
Total Long-Term Liabilities | 139.77 | 149.28 | 164.96 | 180.68 | 192.15 | 193.16 |
Total Liabilities | 373.84 | 401.41 | 340.05 | 344.46 | 271.03 | 246.94 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0 | - | - | 0 | 0 | 0 |
Additional Paid-in Capital | 731.15 | 708.97 | 656.87 | 610.27 | 675.12 | 640.1 |
Accumulated Other Comprehensive Income | -0.73 | 0.35 | 0.07 | 0 | -0.15 | - |
Retained Earnings | 268.82 | 160.9 | 2.22 | -143.28 | -272.13 | -453.6 |
Shareholders' Equity | 999.24 | 870.22 | 659.15 | 466.99 | 402.84 | 186.51 |
Total Liabilities & Equity | 1,373 | 1,272 | 999.2 | 811.45 | 673.87 | 433.44 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 153.96 | 163.66 | 179.27 | 193.57 | 191.65 | 191.98 |
Net Cash (Debt) | 513.83 | 611.68 | 287.92 | 159.89 | 131.47 | 42.33 |
Net Cash Growth | 30.69% | 112.45% | 80.07% | 21.62% | 210.62% | 23.11% |
Net Cash Per Share | 8.75 | 10.45 | 4.97 | 2.65 | 2.15 | 0.71 |
Book Value | 999.24 | 870.22 | 659.15 | 466.99 | 402.84 | 186.51 |
Book Value Per Share | 17.01 | 14.86 | 11.39 | 7.74 | 6.59 | 3.15 |
Tangible Book Value | 921.75 | 780.8 | 545.89 | 329.88 | 241.89 | 42.59 |
Tangible Book Value Per Share | 15.69 | 13.34 | 9.43 | 5.46 | 3.96 | 0.72 |